Home > Market > Market Stats >  Divis Laboratories

Divis Laboratories

Sector: Biotechnology & Drugs
Powered by
3684.50 -9.40 (-0.25%)
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y

Price Range

Today’s Low 3610.4
Today’s High 3730.05
52 Week Low 3365.1
52 Week High 5425.0

Key Metrics

  • Market Cap (In Cr) 98054.8
  • Beta 0.4
  • Div. Yield (%) 0.81
  • P/B 8.36
  • TTM P/E 31.04
  • Peg Ratio -1.8
  • Sector P/E 37.72
  • D/E -
  • Open Price 3712
  • Prev Close 3693.9
View All Metrics on Mint Genie

Analysis

Price Analysis
  • 1 Week
    3.17%
  • 3 Months
    1.74%
  • 6 Month
    -16.09%
  • YTD
    -21.05%
  • 1 Year
    -23.15%
Risk Meter
  • 30% Low risk
  • 30% Moderate risk
  • 30% Balanced Risk
  • 30% High risk
  • 30% Extreme risk
Recos
21 Analysts
  • Strong Sell
  • Sell
  • Hold
  • Buy
  • Strong Buy
Analysts' Views
  • Ratings
  • Current
  • Strong Sell
  • 2
  • Sell
  • 3
  • Hold
  • 4
  • Buy
  • 9
  • Strong Buy
  • 3

Financials

  • INCOME
  • BALANCE SHEET
  • Cashflow
  • Period
  • 2022
  • Total Revenue
  • 8959.83
  • Selling/ General/ Admin Expenses Total
  • 677.71
  • Depreciation/ Amortization
  • 311.51
  • Total Operating Expense
  • 5387.35
  • Operating Income
  • 3572.48
  • Net Income Before Taxes
  • 3683.5
  • Net Income
  • 2960.45
  • Diluted Normalized EPS
  • 111.58
  • Period
  • 2021
  • Total Revenue
  • 6969.4
  • Selling/ General/ Admin Expenses Total
  • 1306
  • Depreciation/ Amortization
  • 255.59
  • Total Operating Expense
  • 4354.71
  • Operating Income
  • 2614.69
  • Net Income Before Taxes
  • 2666.04
  • Net Income
  • 1984.29
  • Diluted Normalized EPS
  • 74.91
  • Period
  • 2020
  • Total Revenue
  • 5394.42
  • Selling/ General/ Admin Expenses Total
  • 1061.8
  • Depreciation/ Amortization
  • 186.24
  • Total Operating Expense
  • 3754.2
  • Operating Income
  • 1640.22
  • Net Income Before Taxes
  • 1819.46
  • Net Income
  • 1376.54
  • Diluted Normalized EPS
  • 51.95
  • Period
  • 2019
  • Total Revenue
  • 4946.26
  • Selling/ General/ Admin Expenses Total
  • 881.55
  • Depreciation/ Amortization
  • 168.9
  • Total Operating Expense
  • 3240.75
  • Operating Income
  • 1705.51
  • Net Income Before Taxes
  • 1855.07
  • Net Income
  • 1352.74
  • Diluted Normalized EPS
  • 50.99
  • Period
  • 2018
  • Total Revenue
  • 3912.78
  • Selling/ General/ Admin Expenses Total
  • 757.07
  • Depreciation/ Amortization
  • 142.49
  • Total Operating Expense
  • 2787.3
  • Operating Income
  • 1125.48
  • Net Income Before Taxes
  • 1231.33
  • Net Income
  • 877.01
  • Diluted Normalized EPS
  • 33.2
  • Period
  • 2017
  • Total Revenue
  • 4106.26
  • Selling/ General/ Admin Expenses Total
  • 734.06
  • Depreciation/ Amortization
  • 123.33
  • Total Operating Expense
  • 2743.31
  • Operating Income
  • 1362.95
  • Net Income Before Taxes
  • 1395.34
  • Net Income
  • 1060.42
  • Diluted Normalized EPS
  • 39.96
View detailed financials on Mint Genie

Forecast

Income Sheet (In Cr) Net Income Vs Revenue
Returns Metrics (In Cr) ROA Vs ROE

Technical

Moving Average SMA
  • 5 Day3677.74
  • 10 Day3636.97
  • 20 Day3626.81
  • 50 Day3696.38
  • 100 Day3710.87
  • 300 Day4064.64

Peers

  • Price
  • Ratio
  • Name
  • Latest Price
  • Change
  • % Change
  • 52W High
  • 52W Low
  • Mkt. Cap
  • Cipla
  • 1115.2
  • -2.45
  • -0.22
  • 1121
  • 850
  • 90049.28

Corporate Actions

  • Board Meeting
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
  • Meeting Date
  • Purpose
  • 12-Aug-22
  • Quarterly Results
  • 23-May-22
  • Audited Results & Dividend
  • 11-Feb-22
  • Quarterly Results
  • 04-Feb-22
  • Quarterly Results
  • 06-Nov-21
  • Quarterly Results
  • 07-Aug-21
  • Quarterly Results
  • 29-May-21
  • Audited Results & Final Dividend
  • 06-Feb-21
  • Quarterly Results

Company Profile

ABOUT Divis Laboratories

  • Industry Biotechnology & Drugs
  • ISIN INE361B01024
  • BSE Code 532488
  • NSE Code DIVISLAB

Divi's Laboratories Limited is an India-based company, which is engaged in manufacturing and sale of active pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Company’s products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl and Vigabatrin. The Company’s subsidiaries include Divi’s Laboratories USA, Inc., (Divi’s USA) and Divi’s Laboratories Europe AG (Divi’s Europe).

MANAGEMENT

  • Kiran Divi Chief Executive Officer, Whole-time Director
  • L. Kishore Babu Chief Financial Officer
  • M. Satish Choudhury Chief Compliance Officer, Company Secretary
  • Murali Divi Managing Director, Executive Director
  • Madhusudana Divi Whole-Time Director (Projects)
  • Nilima Divi Whole-Time Director (Commercial)
  • Nimmagadda Ramana Executive Director

Company Summary

DIVIS LABORATORIES SUMMARY

Divis Laboratories is trading 0.25% lower at Rs 3684.50 as compared to its last closing price. Divis Laboratories has been trading in the price range of 3730.05 & 3610.4. Divis Laboratories has given -21.05% in this year & 3.17% in the last 5 days.

 

Divis Laboratories has TTM P/E ratio 31.04 as compared to the sector P/E of 37.72. There are 21 analysts who have initiated coverage on Divis Laboratories. There are 3 analysts who have given it a strong buy rating & 9 analysts have given it a buy rating. 3 analysts have given the stock a sell rating.

 

The company posted a net profit of 702.01 Crores in its last quarter.

 

Listed peers of Divis Laboratories include Sun Pharmaceutical Industries (1.96%), Divis Laboratories (-0.25%), Cipla (-0.22%) etc.

FAQs about Divis Laboratories

Divis Laboratories is trading at 3684.50 as on 30 Sep, 2022 3:48:42 PM. This is -0.25% lower as compared to its previous closing price of 3693.9
The market capitalization of Divis Laboratories is 98054.8 Cr as on 30 Sep, 2022 3:48:42 PM.
The average broker rating on Divis Laboratories is Hold. The breakup of analyst rating is given below -
  • 2 analysts have given a strong sell rating
  • 3 analysts have given a sell rating
  • 4 analysts have given a hold rating
  • 9 analysts have given a buy rating
  • 3 analysts have given a strong buy rating
The 52 wk high for Divis Laboratories is 5425.0 whereas the 52 wk low is 3365.1
Divis Laboratories can be analyzed on the following key metrics -
  • TTM P/E: 31.04
  • Sector P/E: 37.72
  • Dividend Yield: 0.81%
  • D/E ratio: -
Divis Laboratories reported a net profit of 2960.45 Cr in 2022.

Recommended For You

Trending Stocks

×
Get alerts on WhatsApp
Set Preferences My ReadsWatchlistFeedbackRedeem a Gift CardLogout